Inari Medical (Nasdaq:NARI) today announced that it enrolled the first patient in its Defiance trial for evaluating the ClotTriever system.
In August 2022, Inari Medical announced the launch of its Defiance trial for comparing ClotTriever to anticoagulation. Those enrolled in the trial (300 patients total) only have iliofemoral deep vein thrombosis (DVT). The trial spans 60 centers around the world.
Principal investigators Dr. Xhorlina Marko, Dr. Steven Abramowitz and Dr. Stephen Black lead the trial. Marko is based at Beaumont Health, Abramowitz at MedStar Health and Black at Guy’s and St. Thomas’ Hospital (London).
Dr. Abdullah Shaikh of Allegheny Health Network (Pittsburgh, Pennsylvania) enrolled the first patient. He said Inari and the investigators designed the trial to change the standard of care.
“We’re thrilled to enroll the first patient and officially kick off this important clinical trial,” said Shaikh. “ClotTriever is fundamentally different than other DVT treatments.”
Abramowitz added that Defiance should “answer critical questions” about DVT patient management. Prior trials focused on thrombolytic-based interventions, he noted. ClotTriever offers lytic-free thrombectomy to combat the downsides and limitations of previous treatments.
Inari Medical designed ClotTriever to capture and remove large clot burden from big vessels. Treating patients in one single session, it eliminates the need for thrombolytic and a stay in the intensive care unit.
“With six major clinical studies, including two ongoing RCTs, Inari is wholly committed to VTE patients and producing definitive evidence to support our technologies,” said Dr. Thomas Tu, Inari CMO. “None of this is possible without the collaboration and dedication of our clinical trial investigators who continually push the field forward in the name of better patient outcomes.”